Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Has McKesson (MCK) Outpaced Other Medical Stocks This Year?

Published 02/10/2020, 11:30 PM
Updated 07/09/2023, 06:31 AM

Investors focused on the Medical space have likely heard of McKesson (NYSE:MCK), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

McKesson is a member of our Medical group, which includes 901 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MCK is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for MCK's full-year earnings has moved 2.29% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, MCK has returned 17.22% so far this year. In comparison, Medical companies have returned an average of 1.95%. This means that McKesson is performing better than its sector in terms of year-to-date returns.

To break things down more, MCK belongs to the Medical - Dental Supplies industry, a group that includes 22 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, stocks in this group have gained 3.42% this year, meaning that MCK is performing better in terms of year-to-date returns.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

MCK will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.



Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.